Lubrizol will present its latest polymer-based excipient technologies at CPHI Frankfurt, taking place October 28–30, 2025, at Stand 8.0M71. The company will showcase solutions aimed at improving the solubility, bioavailability, and palatability of active pharmaceutical ingredients (APIs) and nutraceuticals.

Key products on display include:

• Apisolex: A polyamino acid-based excipient for injectable and parenteral formulations, capable of enhancing API solubility up to 50,000-fold, with high drug loading and simplified formulation processes.
• Apinovex: Designed for oral dosage forms, this excipient improves dissolution of BCS Class II and IV APIs by up to 10 times, supports high drug loading (up to 80%), and enables stable amorphous solid dispersions and innovative oral formats.
• Carbopol: A versatile excipient used in oral and topical formulations for over 60 years. It offers benefits such as improved drug delivery, tablet hardness, taste-masking, and enhanced stability—particularly useful in pediatric, geriatric, and supplement applications.

Lubrizol also offers formulation expertise to help partners accelerate product development.